Welcome to our dedicated page for Brainstorm Cell Therapeutics I news (Ticker: BCLI), a resource for investors and traders seeking the latest updates and insights on Brainstorm Cell Therapeutics I stock.
BrainStorm Cell Therapeutics Inc. develops autologous adult stem cell therapeutics for neurodegenerative diseases, with news centered on its investigational NurOwn® platform for amyotrophic lateral sclerosis. NurOwn uses bone marrow-derived mesenchymal stem cells expanded and differentiated ex vivo into neurotrophic factor-secreting MSC-NTF cells designed to deliver neurotrophic factors and immunomodulatory cytokines.
Company updates commonly cover financial results, private placements and working-capital actions, regulatory engagement with the FDA, manufacturing readiness and clinical development activities tied to the Phase 3b ENDURANCE study. Corporate updates also address the completed transition of BCLI common stock from Nasdaq listing to OTCQB quotation.
BrainStorm Cell Therapeutics (OTCQB:BCLI) entered into May 2026 private placement agreements generating $400,000 in gross proceeds, priced at $0.95 per share, a 37.6% premium to the prior close of $0.69. Investors receive 120% warrant coverage at a $1.45 exercise price with a five-year term.
Two placements totaling $200,000 closed May 11, 2026, and the final one closed May 18, 2026. These transactions follow a $2.0 million February 2026 raise, bringing H1 2026 capital raises to $2.4 million, which management aims to use as bridge financing ahead of the planned Phase 3b ENDURANCE trial.
BrainStorm Cell Therapeutics (OTCQB:BCLI) reported Q1 2026 results and an update on its NurOwn ALS program. The company is preparing the Phase 3b ENDURANCE trial, targeting about 200 earlier-stage ALS patients, with Part A intended to support a new BLA submission if successful.
Q1 2026 net loss was $2.1M vs. $2.9M in Q1 2025, with R&D at $0.8M and G&A at $1.3M. Cash, cash equivalents and restricted cash totaled about $0.2M on March 31, 2026. BrainStorm closed private placements totaling $2.2M in Q1 and early Q2 2026.
BrainStorm Cell Therapeutics (OTCQB: BCLI) reported full-year 2025 results and a corporate update on March 31, 2026. The company closed two private placements in February 2026 totaling $2.0 million and plans a Phase 3b ENDURANCE study of NurOwn for ALS.
Key 2025 figures: cash ~$0.3M at year-end, R&D $4.2M, G&A $5.8M, and net loss ~$10.3M. Expanded Access Program patients show prolonged survival (mean ~84 months; 5/10 alive).
Brainstorm Cell Therapeutics (OTCQB: BCLI) completed a second definitive private placement for $1.0 million, bringing February 2026 proceeds to $2.0 million.
Shares were priced at $0.60 with 120% warrant coverage at a $1.00 exercise price; funding will be drawn in up to eight staged installments to support working capital and preparatory work for a planned Phase 3b NurOwn trial.
Brainstorm Cell Therapeutics (OTCQB:BCLI) announced a $1.0 million strategic private placement priced at $0.60 per share, a premium to the $0.54 close on Feb 9, 2026. The deal includes 120% warrant coverage exercisable at $1.00 for five years.
Funding is split into two tranches ($500,000 received; $500,000 due within 30 days). The company must file resale registration within 45 days and said proceeds will support regulatory work, prepayments for the planned Phase 3b NurOwn trial in ALS, and general corporate purposes. An 8-K was filed Feb 13, 2026.
BrainStorm Cell Therapeutics (OTCQB: BCLI) reported Q3 2025 results and a corporate update on Nov 14, 2025. The FDA cleared the planned Phase 3b ENDURANCE study of NurOwn for ALS, which is expected to enroll ~200 participants and includes a 24-week randomized double-blind period plus a 24-week open-label extension. Part A's primary endpoint is change on the ALSFRS-R at Week 24, with data intended to support a BLA submission. The company noted a Citizen Petition filed by ALS community representatives and said it did not participate in that filing. Financials: cash and equivalents were approximately $0.23M at Sept 30, 2025; Q3 net loss was $2.1M and net loss per share was $0.19.
BrainStorm Cell Therapeutics (OTCQB: BCLI), a developer of adult stem cell therapeutics, reported Q2 2025 financial results and significant developments for its NurOwn® therapy. The company received FDA clearance for a Phase 3b trial (ENDURANCE) designed to support a potential BLA submission, planning to enroll approximately 200 participants.
Key highlights include promising survival data from the NurOwn Expanded Access Program, showing 100% of participants surviving beyond 5 years from ALS symptom onset, with a median survival of 6.8 years. The company signed an LOI with Minaris Advanced Therapies for manufacturing support and presented breakthrough pharmacogenomic data at ISCT 2025.
Financial results show cash position of $1.03 million, with a quarterly net loss of $2.9 million ($0.34 per share), compared to $2.54 million ($0.60 per share) in Q2 2024.
BrainStorm Cell Therapeutics (OTCQB: BCLI), a developer of adult stem cell therapeutics for neurodegenerative diseases, will host its Q2 2025 financial results conference call on August 14, 2025, at 8:30 AM ET.
The call will feature presentations from key executives including CEO Chaim Lebovits, COO Hartoun Hartounian, CMO Bob Dagher, and Interim CFO Alla Patlis, followed by a Q&A session. Investors can submit questions in advance to q@brainstorm-cell.com by August 12, 2025, at 10:00 AM ET.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced its delisting from the Nasdaq Capital Market effective July 18, 2025, due to non-compliance with minimum shareholder equity requirements. The company's shares will transition to the OTCQB Venture Market under the same symbol BCLI.
CEO Chaim Lebovits emphasized that despite this setback, the company remains committed to advancing NurOwn for ALS patients, including preparations for a pivotal Phase 3b trial under an FDA Special Protocol Assessment agreement. The delisting will not affect BrainStorm's business operations, R&D efforts, or SEC compliance obligations.
BrainStorm Cell Therapeutics (NASDAQ: BCLI) announced that the FDA will review a Citizen Petition requesting a new evaluation of data supporting NurOwn®, their ALS treatment therapy. The company, while not involved in the petition's submission, welcomes this development as an opportunity to reaffirm NurOwn's potential effectiveness.
Key clinical findings include: statistically significant functional improvement in patients with baseline ALSFRS-R scores ≥35, preservation of two more ALSFRS-R points compared to placebo, and remarkable survival data showing median survival of 6.8 years in Expanded Access Program participants.
BrainStorm will proceed with its planned Phase 3b ENDURANCE trial under FDA Special Protocol Assessment while exploring potential regulatory pathways for NurOwn access.